Monoclonal antibodies against abcb1

Doxorubicin (Dox), paclitaxel, verapamil, 3-(4,5-dimethylthiazol-yl)-2,5-diphenylLapatinibrazolium bromide (MTT) and rhodamine 123 (Rho 123) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Lapatinib was purchased from LC laboratories (Woburn, MA, USA). Dulbecco's modified Eagle's medium (DMEM) were products of Gibco BRL (Grand Island, NY, USA). Monoclonal antibodies against ABCB1 were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). Other routine laboratory reagents were of analytical grade obtained from various commercial sources (Guangzhou, China).

Cetuximab was purchased from Boehringer Ingelheim Pharma GmbH & Co. KG. Monoclonal antibodies against ABCB1, AKT, p-AKT, ERK, p-ERK and EGFR were purchased from Santa Cruz Biotechnology (CA, USA). Monoclonal antibody against p-EGFR and BIM were purchased from Cell Signaling Technology (Danvers, MA). Flow cytometry antibody against ABCB1 and IgG2α were purchased from BD Biosciences (San Jose, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Kangchen Co. (Shanghai, China). Dulbecco's modified Eagle's medium (DMEM) and RPMI 1640 medium were purchased from Life Technologies, Inc. Rho 123, 1-(4, 5-dimethylthiazol-2-yl)-3, 5-diphenylformazan (MTT), paclitaxel, DOX, verapamil (VRP), vincristine (VCR), topotecan, cisplatin, MK571, fumitremorgin C (FTC) and other chemicals were purchased from Sigma Chemical Co (St. Louis, MO).